These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28295185)

  • 1. Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.
    Höring E; Montraveta A; Heine S; Kleih M; Schaaf L; Vöhringer MC; Esteve-Arenys A; Roué G; Colomer D; Campo E; Ott G; Aulitzky WE; van der Kuip H
    Br J Haematol; 2017 May; 177(4):557-561. PubMed ID: 28295185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
    Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
    Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
    Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
    Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
    Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
    Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA.
    Heine S; Kleih M; Giménez N; Böpple K; Ott G; Colomer D; Aulitzky WE; van der Kuip H; Silkenstedt E
    J Hematol Oncol; 2018 Sep; 11(1):112. PubMed ID: 30180865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477.
    Mallick DJ; Soderquist RS; Bates D; Eastman A
    Cell Death Dis; 2019 Feb; 10(3):185. PubMed ID: 30796196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.
    Nguyen T; Parker R; Zhang Y; Hawkins E; Kmieciak M; Craun W; Grant S
    BMC Cancer; 2018 Nov; 18(1):1129. PubMed ID: 30445933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.
    Chiou JT; Huang NC; Huang CH; Wang LJ; Lee YC; Shi YJ; Chang LS
    J Cell Physiol; 2021 Nov; 236(11):7356-7375. PubMed ID: 33982799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death.
    Liu Y; Mondello P; Erazo T; Tannan NB; Asgari Z; de Stanchina E; Nanjangud G; Seshan VE; Wang S; Wendel HG; Younes A
    Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12034-12039. PubMed ID: 30404918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.
    Booher RN; Hatch H; Dolinski BM; Nguyen T; Harmonay L; Al-Assaad AS; Ayers M; Nebozhyn M; Loboda A; Hirsch HA; Zhang T; Shi B; Merkel CE; Angagaw MH; Wang Y; Long BJ; Lennon XQ; Miselis N; Pucci V; Monahan JW; Lee J; Kondic AG; Im EK; Mauro D; Blanchard R; Gilliland G; Fawell SE; Zawel L; Schuller AG; Strack P
    PLoS One; 2014; 9(10):e108371. PubMed ID: 25289887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.
    Gregory GP; Hogg SJ; Kats LM; Vidacs E; Baker AJ; Gilan O; Lefebure M; Martin BP; Dawson MA; Johnstone RW; Shortt J
    Leukemia; 2015 Jun; 29(6):1437-41. PubMed ID: 25578475
    [No Abstract]   [Full Text] [Related]  

  • 12. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
    Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
    Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL2 inhibitor ABT-199 and BCL2L1 inhibitor WEHI-539 coordinately promote NOXA-mediated degradation of MCL1 in human leukemia cells.
    Chiou JT; Lee YC; Wang LJ; Chang LS
    Chem Biol Interact; 2022 Jul; 361():109978. PubMed ID: 35561756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
    Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P
    Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.
    Montraveta A; Xargay-Torrent S; Rosich L; López-Guerra M; Roldán J; Rodríguez V; Lee-Vergés E; de Frías M; Campàs C; Campo E; Roué G; Colomer D
    Oncotarget; 2015 Aug; 6(25):21159-72. PubMed ID: 26110568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
    Teh TC; Nguyen NY; Moujalled DM; Segal D; Pomilio G; Rijal S; Jabbour A; Cummins K; Lackovic K; Blombery P; Thompson E; Ekert PG; Lessene G; Glaser SP; Huang DCS; Roberts AW; Guthridge MA; Wei AH
    Leukemia; 2018 Feb; 32(2):303-312. PubMed ID: 28751770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoic acid/alpha-interferon combination inhibits growth and promotes apoptosis in mantle cell lymphoma through Akt-dependent modulation of critical targets.
    Dal Col J; Mastorci K; Faè DA; Muraro E; Martorelli D; Inghirami G; Dolcetti R
    Cancer Res; 2012 Apr; 72(7):1825-35. PubMed ID: 22311672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.
    Bates DJ; Salerni BL; Lowrey CH; Eastman A
    Cancer Biol Ther; 2011 Aug; 12(4):314-25. PubMed ID: 21768777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
    Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
    Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma.
    Kuroda Y; Koyama D; Kikuchi J; Mori S; Ichinohe T; Furukawa Y
    Leuk Res; 2021 Dec; 111():106672. PubMed ID: 34332177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.